Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18) (hansenula polymorpha)
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The quadrivalent recombinant human papillomavirus vaccine (types 6, 11, 16, 18) produced in *Hansenula polymorpha* is a prophylactic vaccine developed by the Chengdu Institute of Biological Products (CDIBP), a subsidiary of China National Biotec Group (CNBG/Sinopharm). This vaccine is designed to prevent infections and associated diseases caused by HPV types 6, 11, 16, and 18, including cervical cancer, vulvar and vaginal cancers, and genital warts (condyloma acuminata). Unlike the first-generation quadrivalent vaccine (Gardasil), which utilizes *Saccharomyces cerevisiae*, this product employs the methylotrophic yeast *Hansenula polymorpha* as the expression system for the L1 major capsid proteins. These proteins self-assemble into non-infectious virus-like particles (VLPs) that mimic the structure of the native virus to induce a robust neutralizing antibody response. It was approved by China's National Medical Products Administration (NMPA) in early 2024 for use in females aged 9 to 45 years.
- Brand names
- Gengle
- Other names
- Recombinant Human Papillomavirus Quadrivalent (6, 11, 16, 18) Vaccine (Hansenula polymorpha)CDIBP HPV4Gengle HPV Vaccine
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18) (hansenula polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18) (hansenula polymorpha).